Table 2.
Cox regression analysis of overall survival of male patients with initial computed tomography scan
| Univariable | Multivariable | |||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age | 1.016 (1.003–1.029) | 0.018 | ||
| ECOG performance score ≥ 1 | 1.211 (0.898–1.632) | 0.209 | ||
| Type 2 diabetes | 1.113 (0.861–1.439) | 0.415 | ||
| Dyslipidaemia | 1.080 (0.690–1.692) | 0.736 | ||
| CCI ≥ 10 | 1.550 (1.082–2.221) | 0.017 | 1.332 (0.902–1.968) | 0.149 |
| Size | 1.058 (1.001–1.119) | 0.047 | 1.055 (0.977–1.139) | 0.172 |
| Biliary obstruction | 1.144 (0.802–1.631) | 0.459 | ||
| Duodenal obstruction | 0.978 (0.434–2.202) | 0.957 | ||
| Peritoneal seeding | 0.883 (0.673–1.159) | 0.370 | ||
| CA 19‐9 ≥ 1000 U/mL | 1.268 (0.985–1.632) | 0.065 | 1.235 (0.961–1.587) | 0.099 |
| First CTx: FOLFIRINOX | 0.877 (0.661–1.165) | 0.365 | ||
| Conversion surgery a | 0.369 (0.200–0.678) | 0.001 | 0.391 (0.208–0.738) | 0.004 |
| MA ≥ 44.4 HU | 0.700 (0.544–0.900) | 0.005 | 0.706 (0.538–0.925) | 0.012 |
| SMI ≥ 41.9 cm2/m2 | 0.621 (0.470–0.820) | <0.001 | 0.590 (0.435–0.800) | <0.001 |
| VATI ≥40.0 cm2/m2 | 1.226 (0.943–1.593) | 0.128 | 1.247 (0.922–1.687) | 0.152 |
| SATI ≥ 42.8 cm2/m2 | 1.221 (0.911–1.637) | 0.181 | ||
Abbreviations: CA 19‐9, carbohydrate antigen 19‐9; CCI, Charlson comorbidity index; CI, confidence interval; CTx, chemotherapy; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; MA, muscle attenuation; SATI, subcutaneous adipose tissue index; SMI, skeletal muscle index; VATI, visceral adipose tissue index.
a
Time‐varying covariate.